Fosun Pharma gains approvals for two novel therapies

Shanghai Fosun Pharmaceutical Group (SSE:600196) announced that its holding subsidiaries have received drug registration approvals from the National Medical Products Administration (NMPA) for two innovative therapies. The first approval is for FCN-159, a MEK1/2 selective inhibitor, marketed as "Fumaining" (芦沃美替尼片). This drug is indicated for treating adult patients with Langerhans cell histiocytosis (LCH) and histiocytic tumors, as well as pediatric and adolescent patients (2 years and older) with Type I neurofibromatosis (NF1) and symptomatic, inoperable plexiform neurofibromas (PN). The company has invested CNY 598 million in its research and development.